Child dies in Chinese gene-editing trial for Duchenne muscular dystrophy, raising safety and transparency concerns
A child has died during a gene-editing clinical trial in China conducted by a Chinese startup for Duchenne muscular dystrophy treatment, reigniting debate about regulatory oversight and transparency in the country's biotech sector.
